术前风险评分在现代破裂性腹主动脉瘤经验中的准确性获证实
本研究对2002至2018年单中心收治的417例破裂性腹主动脉瘤患者进行回顾性分析,并在现代队列中前瞻性验证4分术前风险评分。结果显示评分与30天死亡率呈显著线性趋势,0分死亡率14.6%,1分35.7%,2分68.4%,3或4分100%。
要点
- 4分术前风险评分可准确预测现代破裂性腹主动脉瘤患者30天死亡率。
- 评分0、1、2、3或4分对应30天死亡率分别为14.6%、35.7%、68.4%、100%。
- 评分有助于与转诊医生、患者及家属讨论治疗方案和转运决策。
核心结论
- 简单4分术前风险评分在现代破裂性腹主动脉瘤患者中验证准确,可预测30天死亡率。
研究设计与样本
- 单中心回顾性Review,纳入2002年1月至2018年12月收治的417例破裂性腹主动脉瘤患者,按机构实践变化分为三个队列。
- 现代队列118例,其中开放修复45例(38.1%),EVAR 61例(51.7%),仅舒适治疗12例(10.2%)。
主要发现
- 排除12例未修复患者后,术前风险评分与30天死亡率在所有患者(P < .0001)、开放修复患者(P = .0003)和EVAR患者(P < .0001)中均呈显著线性趋势。
- 调整Harborview风险评分后,开放修复与EVAR的30天死亡率分别为41.3%和31.6%(P = .2)。
- 所有修复患者中,评分0、1、2、3或4分的30天死亡率分别为14.6%、35.7%、68.4%、100%。
关键数值与推荐
- 术前风险评分每项1分:年龄>76岁、pH<7.2、肌酐>2 mg/dL、任何低血压发作(收缩压<70 mm Hg)。
- 既往回顾性分析报告死亡率:1分22%,2分69%,3分78%,4分100%。
临床怎么用
- 该评分可用于与转诊医生、患者及家属讨论治疗方案,辅助转运和治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Various risk score calculators used to predict 30-day mortality after treatment of ruptured abdominal aortic aneurysms (rAAAs) have produced mixed results regarding their usefulness and reproducibility. We prospectively validated the accuracy of our preoperative scoring system in a modern cohort of patients with rAAAs. METHODS: A retrospective review of all patients wiith rAAAs who had presented to a single academic center from January 2002 to December 2018 was performed. The patients were divided into three cohorts according to when the institutional practice changes had occurred: the pre-endovascular aneurysm repair (EVAR) era (January 2002 to July 2007), the pre-Harbor View risk score era (August 2007 to October 2013), and the modern era (November 2013 to December 2018). The primary outcome measure was 30-day mortality. Our preoperative risk score assigns 1 point for each of the following: age >76 years, pH <7.2, creatinine >2 mg/dL, and any episode of hypotension (systolic blood pressure <70 mm Hg). The previously reported mortality from a retrospective analysis of the first two cohorts was 22% for 1 point, 69% for 2 points, 78% for 3 points, and 100% for 4 points. The goal of the present study was to prospectively validate the Harborview scoring system in the modern era. RESULTS: During the 17-year study period, 417 patients with rAAAs were treated at our institution. Of the 118 patients treated in the modern era, 45 (38.1%) had undergone open aneurysm repair (OAR), 61 (51.7%) had undergone EVAR, and 12 (10.2%) had received comfort measures only. Excluding the 12 patients without aneurysm repair, we found a statistically significant linear trend between the preoperative risk score and subsequent 30-day mortality for all patients combined (P < .0001), for OAR patients alone (P = .0003), and for EVAR patients alone (P < .0001). After adjustment for the Harborview risk score, the 30-day mortality was 41.3% vs 31.6% after OAR vs EVAR, respectively (P = .2). For all repairs, the 30-day mortality was 14.6% for a score of 0, 35.7% for a score of 1, 68.4% for a score of 2, and 100% for a score of 3 or 4. CONCLUSIONS: Our results, representing one of the largest modern series of rAAAs treated at a single institution, have confirmed the accuracy of a simple 4-point preoperative risk score in predicting 30-day mortality in the modern rAAA patient. Such tools should be used when discussing the treatment options with referring physicians, patients, and their family members to help guide transfer and treatment decision-making.
引用
- Hemingway JF, French B, Caps M, et al. Preoperative risk score accuracy confirmed in a modern ruptured abdominal aortic aneurysm experience. J Vasc Surg. 2021. PMID: 33957228. doi:10.1016/j.jvs.2021.04.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。